Axol Bioscience acquires ophthalmology business from Newcells Biotech

·  Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models 

Axol Bioscience acquires Phenocell to advance human disease models

Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatology

CAMBRIDGE / EDINBURGH, UK, and GRASSE, FRANCE, 21 October 2024: Axol Bioscience Ltd.

Axol Bioscience collaborates with StrataStem to deliver stem cell based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

Together, an extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification.

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery

Cambridge and Edinburgh, UK - Axol Bioscience Ltd., an established provider of iPSC-derived cells, media, and characterization services for life science discovery, announces that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for…